Dermata Therapeutics, Inc. DRMA
At closeNov 5, 2026, 4:33 AM EST
Pre-market · Nov 5, 4:33 AM ET
- YTD
- -63.16%
- 1 year
- -73.03%
- Market cap
- 4.24M
- EPS (ttm)
- -4.39
- Shares out
- 2.04M
- Forward P/E
- -0.32
- YTD return
- -63.16%
- 1-year return
- -73.03%
- Volume
- 51.88K
- Avg volume
- 3.44M
- Open
- 0.8444
- Previous close
- 0.8487
- Day's range
- 0.8032 – 0.8696
- 52-week range
- 0.603 – 4.66
- Beta
- 0.79
- Price target
- 6.00 (+601.9%)
2Y -12.0450 (-93.37%)
Key statistics
- Enterprise value
- -3.38M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.24M
- Total cash
- 4.95M
- Total debt
- 0
- Return on equity
- -173.01%
- Short % of float
- 6.28%
- 50-day average
- 1.27
- 200-day average
- 2.84
Analyst view
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -2.04 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -4.18 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -7.05 | — | — |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -3.15 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -8.10 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -9.45 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 2024 | Maxim Group | main | Buy | Buy |
| Mar 23, 2023 | Maxim Group | main | — | Buy |
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dermatarx.com
News
Dermata Therapeutics Enrolls First Participant In Its Clinical Trial Evaluating Tome Clearing Treatment For Acne; Expects To Launch This Second Commercial Product In H1 2027 
Why Is Dermata Therapeutics Stock Gaining Thursday? 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
Your note
Sign in to keep a note on DRMA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.14% | 2,892 | 3.56K | Sep 29, 2024 |
| Wells Fargo & Company | 0.10% | 2,045 | 2.52K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 1,497 | 1.84K | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 10 | 12 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.32% | 6,582 | 8.10K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 1,826 | 2.25K | Oct 30, 2024 |